Group Gp Lp Column III Sells 3,511,826 Shares of Tenaya Therapeutics (NASDAQ:TNYA) Stock

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) major shareholder Group Gp Lp Column III sold 3,511,826 shares of the company’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $0.56, for a total value of $1,966,622.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Group Gp Lp Column III also recently made the following trade(s):

• On Tuesday, February 24th, Group Gp Lp Column III sold 658,440 shares of Tenaya Therapeutics stock. The stock was sold at an average price of $0.62, for a total transaction of $408,232.80.
• On Wednesday, February 11th, Group Gp Lp Column III sold 4,056,573 shares of Tenaya Therapeutics stock. The shares were sold at an average price of $0.68, for a total transaction of $2,758,469.64.
• On Tuesday, February 10th, Group Gp Lp Column III sold 343,717 shares of Tenaya Therapeutics stock. The stock was sold at an average price of $0.82, for a total transaction of $281,847.94.

Tenaya Therapeutics Stock Performance

Shares of Tenaya Therapeutics stock opened at $0.56 on Friday. The firm has a market cap of $91.99 million, a PE ratio of -0.72 and a beta of 3.18. The firm’s 50-day simple moving average is $0.72 and its 200-day simple moving average is $1.14. Tenaya Therapeutics, Inc. has a 1 year low of $0.36 and a 1 year high of $2.35.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on TNYA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tenaya Therapeutics in a report on Wednesday, January 21st. Morgan Stanley set a $2.00 price target on shares of Tenaya Therapeutics in a research report on Thursday, January 8th. Canaccord Genuity Group cut their target price on shares of Tenaya Therapeutics from $6.00 to $5.00 and set a “buy” rating on the stock in a report on Thursday, December 18th. Chardan Capital lowered their target price on Tenaya Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a report on Friday, December 12th. Finally, HC Wainwright dropped their price target on Tenaya Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a research report on Friday, December 12th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $4.50.

Hedge Funds Weigh In On Tenaya Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Mirador Capital Partners LP increased its stake in Tenaya Therapeutics by 38.2% during the 3rd quarter. Mirador Capital Partners LP now owns 23,500 shares of the company’s stock valued at $38,000 after buying an additional 6,500 shares during the period. Scientech Research LLC acquired a new position in shares of Tenaya Therapeutics during the third quarter valued at approximately $27,000. Geode Capital Management LLC increased its stake in shares of Tenaya Therapeutics by 1.5% during the fourth quarter. Geode Capital Management LLC now owns 1,193,355 shares of the company’s stock valued at $849,000 after acquiring an additional 17,820 shares during the period. CWM LLC raised its holdings in Tenaya Therapeutics by 25.2% during the second quarter. CWM LLC now owns 90,087 shares of the company’s stock worth $55,000 after purchasing an additional 18,142 shares in the last quarter. Finally, Cetera Investment Advisers lifted its position in Tenaya Therapeutics by 107.0% in the fourth quarter. Cetera Investment Advisers now owns 106,425 shares of the company’s stock worth $76,000 after purchasing an additional 55,000 shares during the period. Institutional investors own 90.54% of the company’s stock.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of gene therapy solutions for cardiovascular diseases. Leveraging a proprietary adeno‐associated virus (AAV) platform, the company aims to deliver durable, one‐time treatments for patients suffering from genetic cardiomyopathies and other inherited heart disorders. Its research programs center on optimizing vector design, delivery methods and manufacturing processes to enhance tissue specificity and minimize immune responses.

Founded in 2018 and headquartered in San Carlos, California, Tenaya has built a diversified pipeline of product candidates targeting conditions such as hypertrophic cardiomyopathy and other genetically driven forms of heart disease.